Villareal K M, Cook R A, Galgiani J N, Wenzel R P, Pappas P G, Pottage J C, Gallis H A, Crane L R
Medical Service, Veterans Administration Medical Center, Tucson, AZ 85723.
Diagn Microbiol Infect Dis. 1994 Feb;18(2):89-94. doi: 10.1016/0732-8893(94)90071-x.
We performed antifungal susceptibility tests with cilofungin (LY121019), amphotericin B, and flucytosine against 38 strains of yeasts from patients with esophagitis or fungemia either before, during, or after treatment with cilofungin. Tests were performed using a macrobroth dilution method similar to that proposed by the National Committee for Clinical Laboratory Standards (M27-P) and two microbroth methods. For cilofungin and amphotericin B, minimum inhibitory concentrations from microbroth tests using Antibiotic Medium 3 (AM3) were systematically lower than results from the other two methods that utilized RPMI-1640 medium (RPMI). AM3 did not provide any greater degree of in vitro correlation with clinical results than did RPMI. We conclude that cilofungin and possibly other congeners of the echinocandin class of antifungal agents can effectively be studied using the proposed National Committee for Clinical Laboratory Standards method.
我们用西洛芬净(LY121019)、两性霉素B和氟胞嘧啶对38株来自食管炎或真菌血症患者的酵母菌株进行了抗真菌药敏试验,这些菌株分别处于接受西洛芬净治疗之前、治疗期间或治疗之后。试验采用了一种类似于美国国家临床实验室标准委员会(M27 - P)提议的常量肉汤稀释法以及两种微量肉汤法。对于西洛芬净和两性霉素B,使用抗生素培养基3(AM3)进行微量肉汤试验得出的最低抑菌浓度,系统性地低于使用RPMI - 1640培养基(RPMI)的其他两种方法得出的结果。与RPMI相比,AM3在体外与临床结果的相关性方面并未表现出更高的程度。我们得出结论,使用美国国家临床实验室标准委员会提议的方法能够有效地研究西洛芬净以及棘白菌素类抗真菌药物中可能的其他同类物。